Drug intelligence / Profile preview

NOP16 small interfering RNA + NOP16 short hairpin RNA

Development stage
Preclinical
Lead developer
Boston Children's Hospital
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01

Overview

NOP16 small interfering RNA (siRNA) and NOP16 short hairpin RNA (shRNA) are experimental RNA interference (RNAi) therapies designed to inhibit the expression of Nucleolar protein 16 (NOP16). NOP16 has been characterized as an endogenous mammalian protein that functions as a histone H3K27 mimic, competing with histone H3 for binding to the Polycomb Repressive Complex 2 (PRC2) component EED and the H3K27 demethylase JMJD3. By sequestering EED from the nucleoplasm to the nucleolus, NOP16 negatively regulates H3K27 trimethylation, thereby derepressing genes involved in cell cycle progression, growth, and apoptosis. In breast cancer, particularly triple-negative breast cancer (TNBC), NOP16 is frequently overexpressed and correlates with poor prognosis. The use of siRNA and shRNA to deplete NOP16 levels has demonstrated significant anti-tumor activity in preclinical models, including induction of cell cycle arrest, inhibition of cell proliferation, and reduction of tumor growth in vivo.

Other names
NOP16 siRNANOP-16 siRNANOP 16 siRNANOP16 shRNANOP-16 shRNANOP 16 shRNANucleolar protein 16 siRNANucleolar protein 16 shRNA
02

Targets

NOP16 (Nucleolar protein 16)

Beyond the preview

Go deeper on NOP16 small interfering RNA + NOP16 short hairpin RNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NOP16 small interfering RNA + NOP16 short hairpin RNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call